Characterization of the BclI Polymorphism in the Glu
* address correspondence to this author at: Centre de Recherche, Hô pital Sainte-Justine, 3175 Cô te Ste-Catherine, Montréal (Québec), H3T 1C5 Canada; fax 514-345-4731, e-mail maja.krajinovic@umontreal.ca) Glucocorticoids (GCs) have a major antiproliferative effect, which has led to the use of their synthetic homologs for immunosuppression, treatment of inflammation, and induction of cytotoxicity (1, 2 ) . GCs exert their effect by binding to an intracellular GC receptor (GR), forming a complex that translocates to the nucleus, where GCs then regulate the expression of target genes interacting with promoter GC-responsive elements (1 ) . The different GR forms, resulting from GR gene variability, can affect the regulation of many biological functions, such as hypothalamic-pituitary-adrenal axis regulation and GC responsiveness, thereby underlying susceptibility to many diseases. Indeed, GR mutations have been associated with altered cardiovascular function, metabolic disturbances, and hematologic malignancies (3) (4) (5) . Likewise, functional GR variability might affect the therapeutic response to corticosteroid drugs (5 ) . Identification of different GR gene variants may thus be helpful in assessing the role of the GR gene in disease susceptibility or in adjudging predisposition to corticosteroid-associated adverse drug reactions.
Several polymorphisms of the GR gene, which might have an impact on GC sensitivity, have been reported (6 -8 ) . Among these, the BclI polymorphism was identified by Southern blotting using human GR cDNA-specific probes (9 ) that identified two alleles with fragment lengths of 4.5 and 2.3 kb. Several clinical investigations have subsequently suggested that this GR polymorphism is linked to altered GR function (6, 10 -15 ) . An association between the BclI polymorphism and changes in tissuespecific corticosteroid sensitivity, as well as with poor feedback regulation of the hypothalamic-pituitary-adrenal axis, has been reported (6, 10 ) . This was further documented by association of the BclI polymorphism with abdominal obesity (11, 12 ) , insulin resistance (6, 13 ) , and development of an atherogenic profile (6, 14 ) . Similarly, the larger allele of BclI is more frequent in a group of individuals genetically predisposed to develop hypertension (15 ) . The molecular identity of this polymorphism, however, is still unclear, and its analysis has been based on the laborious and time-consuming Southern blot approach, which requires large quantities of DNA and is difficult to apply to large-scale genotyping (6, 10 -15 ) .
Here we present the characterization of the BclI polymorphism, as well as the application of two simple genotyping assays for its detection: PCR with restriction fragment length polymorphism (RFLP) analysis and al-lele-specific oligonucleotide (ASO) hybridization. Using these approaches, we assessed the frequency of this polymorphism in populations of different origin.
The BclI site was suggested to be situated in either the first or second intron of the GR gene (6 ) . To search for BclI sites in these gene segments, we used the genomic sequence derived from human chromosome 5 contig (GenBank accession no. NT_029289), on which the exon/ intron boundaries were positioned according to the GR mRNA sequence information (GenBank accession no. NM_000176.1) and BLAST search (http://www.ncbi.nlm. nih.gov/BLAST/). The genomic sequence corresponding to the first two introns was analyzed for BclI restriction sites using WebCutter 2.0 software (http://www. firstmarket.com/cutter/cut2.html). We found three BclI sites, one in intron 1 and two in intron 2, whose relative positions to the exon 2/intron 2 boundary are indicated in Fig. 1A . Only the polymorphic BclI site in intron 2, 647 bp from exon/intron junction, produced the fragment sizes corresponding to those obtained by Southern blot exper- 2) and two homozygous for the larger allele (lanes 3 and 4) . The G-to-C substitution in intron 2 at position ϩ646 is indicated by the arrow. iments (i.e., fragments of 2.2 kb generated in the presence and 3.9 kb in the absence of the BclI site; Fig. 1A ). Although the size of the larger allele would be slightly different from that reported previously (9 ) , no other BclI site produced a fragment of similar size.
Using this information, we designed primers flanking the BclI site at position ϩ647 (forward, 5Ј-AAATT-GAAGCTTAACAATTTTGGC-3Ј; reverse, 5Ј-GCAGT-GAACAGTGTACCAGACC-3Ј) and amplified genomic DNA samples from the Institutional DNA bank of healthy volunteers recruited for the study of human genomic sequences variability.
To confirm the presence of the BclI polymorphism, we digested 10 L of the PCR products with 4 U of BclI (New England BioLabs) for 6 h at 50°C and separated the resulting digested fragments on a 3% agarose gel. Digestion of the PCR product gave the following predicted fragment sizes: 90 and 116 bp in the case of homozygotes for the smaller allele, an additional band of 206 bp for heterozygous individuals, and a single band of 206 bp for larger allele homozygotes (Fig. 1B) . To characterize the underlying base substitution of the BclI polymorphism, we directly sequenced the PCR product using the Thermo Sequenase TM Radiolabeled Terminator Cycle Sequencing Kit (USB Corporation) according to the manufacturer's instructions. We found a G-to-C transition in the second intron, 646 bp from the exon 2/intron 2 junction (Fig. 1C) , that abolished the BclI restriction site (TGATCA to TCATCA, where the underlined bases indicate the transition), thus producing the larger allele. Similar efforts to replace Southern blot analysis by PCR-based methods in analysis of different polymorphisms have been reported in the literature (16, 17 ) .
The identification of the underlying base substitution allowed us to apply a PCR-ASO genotyping assay that, in addition to PCR-RFLP, has been widely used to analyze gene mutations and variations in numerous genes (18 ) . We previously reported the successful use of this approach for large-scale genotyping (19 ) . For this method, PCR products were denatured in 0.33 mol/L NaOH and 16.5 mmol/L EDTA in a total volume of 200 L and subsequently transferred, in duplicate, to a HYBOND-nϩ membrane (Amersham Pharmacia Biotech) and crosslinked to the membrane by use of ultraviolet light. Blots were prehybridized for 30 min at 37°C in 10 mL of a solution containing 1ϫ saline-sodium phosphate-EDTA (SSPE; 150 mmol/L NaCl, 10 mmol/L NaH 2 PO 4 , 1.1 mmol/L EDTA, pH 7.4), 0.75 mol/L NaCl, 70 mmol/L Tris-HCl, pH 7.4), 10 g/L sodium dodecyl sulfate, and 200 mg/L heparin. ASO probes (50 pmoles) were 5Ј-labeled using [␥-32 P]ATP (6000 Ci/mmol) and T4 kinase (Life Technologies) to a specific activity of 1-3 ϫ 10 6 cpm/ pmol. Hybridization with the 5 pmol of ASO-specific probe was carried out for 30 min at 42°C in an excess (10ϫ) of the nonlabeled probe for the other variant allele of the same polymorphism. The membranes were then washed with 2ϫ SSPE containing 1 g/L sodium dodecyl sulfate for 10 min at room temperature and exposed overnight at Ϫ80°C with intensifying screens. Identical twin membranes were hybridized with the allelic probes specific for the G (gag att Gat cag cag) or C (gag att Cat cag cag) variant of the BclI polymorphism and read in parallel. DNA samples of known genotypes served as controls. Representative examples of genotypes obtained by the ASO approach are presented in Fig. 1D .
Using these two genotyping assays, we analyzed DNA samples of individuals from several populations, including Africans, Asians (both Southeast and East Asia), Amerindians, Middle Easterners, and Europeans. Both methods generated concordant results, thus validating the usefulness of both assays. The number of individuals with different genotypes, as well as the frequency of allele C in the tested populations, is given in Table 1 ; the highest frequency of allele C was observed in Asians [mean (SD), 32.8 (8.7)%], and the lowest was in Amerindians [15.2 (6.2)%]. The frequency observed here for Europeans was similar to the one reported for the larger allele in Sweden (6 ) .
We conclude that characterization of the BclI polymorphism, together with the availability of PCR-based genotyping approaches, could allow fast screening of this Despite the predominant role of thyrotropin measurements in the assessment of thyroid status, free thyroxine (FT 4 ) measurements remain useful either when thyrotropin determination is not conclusive or when a diagnosis of thyroid disease must be confirmed (1 ) . Because it represents only a minute fraction (0.02%) of total T 4 (TT 4 ), FT 4 is more difficult to measure (2 ) . Direct equilibrium dialysis (ED) methods are considered analytically accurate (3 ) and are the methods against which others are compared (4 ). Compared with ED, other FT 4 immunoassays may show significant biases related to protein-bound T 4 or to the serum T 4 -binding capacity (sBC: concentration ϫ affinity of binding proteins) (4 -6 ) . We assume assays are calibrated to have roughly the same euthyroid range in samples with normal sBC, and we expect that markedly negative biases may be observed in samples with low sBC and that smaller positive biases may be observed in samples with high sBC (7 ) . The aim of our study was to determine, in clinical samples from euthyroid patients classified into three groups as a function of their low, normal, or high sBC, the bias between FT 4 measured with ED and that measured with nine frequently used immunoassays. We also studied the specificity of each assay method and the concordance of immunoassays with ED.
FT 4 was determined with the Nichols ED/RIA assay (Nichols Institute Diagnostics) and the following nine immunoassays: Elecsys (EL) from Roche Diagnostics, VI-DAS (VD) from bioMérieux, Vitros ECi (VT) from OrthoClinical Diagnostics, GammaCoat 2-step RIA (GC) from DiaSorin, Immulite (IM) from Diagnostic Products Corporation (DPC), Nichols Advantage (AD), AxSYM (AX) from Abbott Diagnostic, ACS (AC) from Bayer Diagnostics, and AIA (AI) from Tosoh Bioscience. All assays were performed in compliance with the manufacturers' instructions. The sBC was calculated by dividing the TT 4 concentration determined with the EL assay by the FT 4 Clinical Chemistry 49, No. 9, 2003 
